Akebia Therapeutics Unveils New Vafseo Clinical Data at ASN Kidney Week 2025
I'm PortAI, I can summarize articles.
Akebia Therapeutics Inc. will present new clinical data on Vafseo® (vadadustat) at the ASN Kidney Week 2025 from November 5-9 in Houston, Texas. The presentation will include results from real-world evidence studies, focusing on the clinical benefits and dosing of Vafseo. Highlights include an oral session on the analysis of deaths and hospitalizations in CKD patients and four posters on dosing recommendations and safety. The studies aim to provide insights into the effectiveness of vadadustat compared to darbepoetin.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments